Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,repurchaseOfStock,otherCashflowsFromFinancingActivities,issuanceOfStock,otherCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,gmtOffSetMilliseconds,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GENPF,146998,59224100,,,-393237,,-393237,74922,0,-389271,-389271,,,,,,0,0,389271,0,-3966,,-393237,-393237,4506608,414200,4653606,197500,5067806,9700762,-5401852,140000,354696,532034,274200,354696,561198,9979,30517,-75675.0,-7938.0,-164573.0,-164573.0,124625.0,-2072.0,189524.0,,,,,,,,286998,en-US,US,EQUITY,False,Delayed Quote,USD,0.0,0.1379 - 0.1379,0.1379,finmb_3102639,Other OTC,CAD,3128,0,0.1378,1378.0,1.0E-4 - 0.2011,-0.06320001,-0.31427157,0.0001,0.2011,-14400000,0.15082222,-0.012922227,-0.08567854,0.1546057,-0.016705707,4,GENIX PHARMACEUTICALS CORPORATI,Genix Pharmaceuticals Corporation,0.1379,1629219231,0.0,0.1379,0.1379,0.1379,2000,POST,PNK,us_market,-0.108053625,8505341,15,America/New_York,EDT,False,False,0,-0.85,,,0.2011,0.0001,0.1508,0.1546,3.13k,,59.22M,,33.51M,44.26%,0.00%,,,,,,,,,,,0.00%,,,,,"Oct 30, 2020","Jan 30, 2021",0.00%,0.00%,-25.46%,-46.97%,,,,,-548.83k,-1.07M,,,532.03k,0.01,15.18k,0.33,2.05,,-314.29k,301.16k,Value,T8V 0Z7,Healthcare,"Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral spray; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and powders. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.",Vancouver,BC,1609372800,Canada,http://www.genixpharm.com,86400,10022 â 102 Avenue,Drug Manufacturers—Specialty & Generic,Grand Prairie
t-1,GENPF,225886,59224100,,,-563068,,-563068,85035,0,-543572,-543572,47.0,-246.0,,,,0,0,543572,0,-19496,,-563068,-563068,4631433,489875,4857319,197500,5347194,9700762,-5008615,140000,165172,696607,349875,165172,715761,7907,116192,36292.0,-57566.0,135883.0,-133003.0,361111.0,-3979.0,93751.0,1229500.0,-455400.0,-960615.0,-484924.0,-20291.0,,,365886,en-US,US,EQUITY,False,Delayed Quote,USD,0.0,0.1379 - 0.1379,0.1379,finmb_3102639,Other OTC,CAD,3128,0,0.1378,1378.0,1.0E-4 - 0.2011,-0.06320001,-0.31427157,0.0001,0.2011,-14400000,0.15082222,-0.012922227,-0.08567854,0.1546057,-0.016705707,4,GENIX PHARMACEUTICALS CORPORATI,Genix Pharmaceuticals Corporation,0.1379,1629219231,0.0,0.1379,0.1379,0.1379,2000,POST,PNK,us_market,-0.108053625,8505341,15,America/New_York,EDT,False,False,0,-0.85,,,0.2011,0.0001,0.1508,0.1546,3.13k,,59.22M,,33.51M,44.26%,0.00%,,,,,,,,,,,0.00%,,,,,"Oct 30, 2020","Jan 30, 2021",0.00%,0.00%,-25.46%,-46.97%,,,,,-548.83k,-1.07M,,,532.03k,0.01,15.18k,0.33,2.05,,-314.29k,301.16k,Value,T8V 0Z7,Healthcare,"Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral spray; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and powders. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.",Vancouver,BC,1609372800,Canada,http://www.genixpharm.com,86400,10022 â 102 Avenue,Drug Manufacturers—Specialty & Generic,Grand Prairie
t-2,GENPF,56180,59224100,,,-71270,,-71270,66981,0,-66980,-66980,-1.0,-1536.0,,,,0,0,66980,0,-4290,,-71270,-71270,1237500,512154,1293680,25000,1805834,5683707,-4445546,337500,55519,560724,174654,55519,568334,7610,6907,-92202.0,18350.0,560321.0,-143587.0,361111.0,-3979.0,1536.0,1229500.0,-455400.0,703909.0,-484924.0,1.0,703908.0,,393680,en-US,US,EQUITY,False,Delayed Quote,USD,0.0,0.1379 - 0.1379,0.1379,finmb_3102639,Other OTC,CAD,3128,0,0.1378,1378.0,1.0E-4 - 0.2011,-0.06320001,-0.31427157,0.0001,0.2011,-14400000,0.15082222,-0.012922227,-0.08567854,0.1546057,-0.016705707,4,GENIX PHARMACEUTICALS CORPORATI,Genix Pharmaceuticals Corporation,0.1379,1629219231,0.0,0.1379,0.1379,0.1379,2000,POST,PNK,us_market,-0.108053625,8505341,15,America/New_York,EDT,False,False,0,-0.85,,,0.2011,0.0001,0.1508,0.1546,3.13k,,59.22M,,33.51M,44.26%,0.00%,,,,,,,,,,,0.00%,,,,,"Oct 30, 2020","Jan 30, 2021",0.00%,0.00%,-25.46%,-46.97%,,,,,-548.83k,-1.07M,,,532.03k,0.01,15.18k,0.33,2.05,,-314.29k,301.16k,Value,T8V 0Z7,Healthcare,"Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral spray; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and powders. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.",Vancouver,BC,1609372800,Canada,http://www.genixpharm.com,86400,10022 â 102 Avenue,Drug Manufacturers—Specialty & Generic,Grand Prairie
t-3,GENPF,-576458,59224100,,,-46551,,-46551,34724,0,-34719,-34719,-5.0,-1635.0,,,,0,0,34719,0,-11832,,-46551,-46551,1237500,582820,661042,112499,1243862,4979798,-4374276,337500,55520,403,245320,55520,6362,5959,6907,143139.0,29174.0,-5625.0,126874.0,361111.0,-3979.0,1113.0,-1257500.0,337500.0,1125000.0,-484924.0,1.0,787500.0,-20000.0,-238958,en-US,US,EQUITY,False,Delayed Quote,USD,0.0,0.1379 - 0.1379,0.1379,finmb_3102639,Other OTC,CAD,3128,0,0.1378,1378.0,1.0E-4 - 0.2011,-0.06320001,-0.31427157,0.0001,0.2011,-14400000,0.15082222,-0.012922227,-0.08567854,0.1546057,-0.016705707,4,GENIX PHARMACEUTICALS CORPORATI,Genix Pharmaceuticals Corporation,0.1379,1629219231,0.0,0.1379,0.1379,0.1379,2000,POST,PNK,us_market,-0.108053625,8505341,15,America/New_York,EDT,False,False,0,-0.85,,,0.2011,0.0001,0.1508,0.1546,3.13k,,59.22M,,33.51M,44.26%,0.00%,,,,,,,,,,,0.00%,,,,,"Oct 30, 2020","Jan 30, 2021",0.00%,0.00%,-25.46%,-46.97%,,,,,-548.83k,-1.07M,,,532.03k,0.01,15.18k,0.33,2.05,,-314.29k,301.16k,Value,T8V 0Z7,Healthcare,"Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral spray; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and powders. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.",Vancouver,BC,1609372800,Canada,http://www.genixpharm.com,86400,10022 â 102 Avenue,Drug Manufacturers—Specialty & Generic,Grand Prairie
